Alaattin ÖZEN, Güntülü AK, Melek AKÇAY, Durmuş ETİZ, Muzaffer METİNTAŞ, Şenay YILMAZ

Lung Stereotactic Body Radiotherapy: Single-Center Experience

OBJECTIVETo evaluate the results of stereotactic body radiotherapy (SBRT) in early-stage lung cancer, lung metastasis,and recurrent lung cancer.METHODSFifty-nine cases that underwent lung SBRT due to early-stage lung cancer, lung metastasis, or lung cancerrecurrence at our Radiation Oncology Department between 2016 and 2019 were retrospectivelyevaluated. The factors affecting overall survival (OS) and progression-free survival (PFS) after SBRTwere investigated.RESULTSAfter SBRT, the median PFS was 12 (0-40) months, whereas OS was 16 (3-44) months. The median durationof OS and PFS were 15 (5-44) and 12.5 (3-40) months, respectively for early-stage lung cancer, 19(3-28) and 12 (0-27) months, respectively for recurrent lung cancer, and 14 (5-25) and 8 (5-25) months,respectively, for lung metastasis. During the 16-month median follow-up after SBRT, eight cases (13.6%)died of cancer, and cancer progressed in 16 cases (27.1%). The factors affecting OS after SBRT were age(p=0.041), KPS (≥80) (p=0.019), and maximum tumor diameter (≤3 cm) (p=0.033) according to univariateanalysis, and KPS (≥80) (p=0.011) and maximum tumor diameter (>3 cm) (p=0.007) according tomultivariate analysis, and the variables affecting PFS after SBRT were GTV (p=0.011) and BED10 (≥100)(p=0.043) for the former, and GTV (p=0.011) for the latter. No patient developed ≥3 radiation pneumonia.CONCLUSIONFollowing lung SBRT, OS was better in younger patients, those with ≥80 KPS or with a tumor diameterof ≤3 cm while PFS was higher in cases with a small GTV volume and those that received BED10≥100radiotherapy dose.

PDF

___

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64(1):9–29.
2. Aberle DR, DeMello S, Berg CD, Black WC, Brewer B, Church TR, et al. Results of the two incidence screenings in the National Lung Screening Trial. N Engl J Med 2013;369(10):920–31.
3. Videtic GMM, Donington J, Giuliani M, Heinzerling J, Karas TZ, Kelsey CR, et al. Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol 2017;7(5):295–301.
4. ABRAMS HL, SPIRO R, GOLDSTEIN N. Metastases in carcinoma; analysis of 1000 autopsied cases. Cancer 1950;3(1):74–85.
5. Pastorino U, Buyse M, Friedel G, Ginsberg RJ, Girard P, Goldstraw P, et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg 1997;113(1):37–49.
6. Ricco A, Davis J, Rate W, Yang J, Perry D, Pablo J, et al. Lung metastases treated with stereotactic body radiotherapy: the RSSearch® patient Registry’s experience. Radiat Oncol 2017;12(1):35.
7. Jeremić B, Videtic GM. Chest reirradiation with external beam radiotherapy for locally recurrent non-small-cell lung cancer: a review. Int J Radiat Oncol Biol Phys 2011;80(4):969–77.
8. Gressen EL, Werner-Wasik M, Cohn J, Topham A, Curran WJ Jr. Thoracic reirradiation for symptomatic relief after prior radiotherapeutic management for lung cancer. Am J Clin Oncol 2000;23(2):160–3.
9. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) Non-Small Cell Lung Cancer Version 2. 2018. Available at: https://www.nccn.org/ professionals/physician_gls/pdf/nscl.pdf. Accessed Mar 13, 2020.
10. Videtic GM, Hu C, Singh AK, Chang JY, Parker W, Olivier KR, et al. A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927). Int J Radiat Oncol Biol Phys 2015;93(4):757–64.
11. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009;50 (Suppl 1):122S–50S.
12. Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 2009;27(20):3290–6.
13. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010;303(11):1070–6.
14. Takeda A, Kunieda E, Sanuki N, Aoki Y, Oku Y, Handa H. Stereotactic body radiotherapy (SBRT) for solitary pulmonary nodules clinically diagnosed as lung cancer with no pathological confirmation: comparison with non-small-cell lung cancer. Lung Cancer 2012;77(1):77–82.
15. Boyer MJ, Ricardi U, Ball D, Salama JK. Ablative Approaches for Pulmonary Metastases. Thorac Surg Clin 2016;26(1):19–34.
16. Amendola BE, Amendola MA, Perez N, Wu X, Suarez JB. Local failure after primary radiotherapy in lung cancer: Is there a role for SBRT?. Rep Pract Oncol Radiother 2015;20(6):440–5.
17. Milano MT, Kong FS, Movsas B. Stereotactic body radiotherapy as salvage treatment for recurrence of nonsmall cell lung cancer after prior surgery or radiotherapy. Transl Lung Cancer Res 2019;8(1):78–87.
18. Milano MT, Constine LS, Okunieff P. Normal tissue toxicity after small field hypofractionated stereotactic body radiation. Radiat Oncol 2008;3:36.
19. Milano MT, Mihai A, Kong FS. Review of thoracic reirradiation with stereotactic body radiation therapy: A focus on toxicity risks. Pract Radiat Oncol 2018;8(4):251–65.
20. Kang KH, Okoye CC, Patel RB, Siva S, Biswas T, Ellis RJ, et al. Complications from Stereotactic Body Radiotherapy for Lung Cancer. Cancers (Basel) 2015;7(2):981–1004.
21. Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007;2(7 Suppl 3):S94–100.
22. Onishi H, Araki T, Shirato H, Nagata Y, Hiraoka M, Gomi K, et al. Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer 2004;101(7):1623–31.
23. Burdick MJ, Stephans KL, Reddy CA, Djemil T, Srinivas SM, Videtic GM. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys 2010;78(4):1033–9.
24. Kohutek ZA, Wu AJ, Zhang Z, Foster A, Din SU, Yorke ED, et al. FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer. Lung Cancer 2015;89(2):115–20.
25. Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Forster K, et al. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 2005;23(6):1136–43.
26. Vahdat S, Oermann EK, Collins SP, Yu X, Abedalthagafi M, Debrito P, et al. CyberKnife radiosurgery for inoperable stage IA non-small cell lung cancer: 18Ffluorodeoxyglucose positron emission tomography/ computed tomography serial tumor response assessment. J Hematol Oncol 2010;3:6.
27. Bollineni VR, Widder J, Pruim J, Langendijk JA, Wiegman EM. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I nonsmall- cell lung cancer predicts local control. Int J Radiat Oncol Biol Phys 2012;83(4):e551–e5.
28. Hoopes DJ, Tann M, Fletcher JW, Forquer JA, Lin PF, Lo SS, et al. FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer. Lung Cancer 2007;56(2):229–34.
29. Mohammed N, Grills IS, Wong CY, Galerani AP, Chao K, Welsh R, et al. Radiographic and metabolic response rates following image-guided stereotactic radiotherapy for lung tumors. Radiother Oncol 2011;99(1):18–22.
30. Koshy M, Malik R, Weichselbaum RR, Sher DJ. Increasing radiation therapy dose is associated with improved survival in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2015;91(2):344–50.
31. Dunlap NE, Larner JM, Read PW, Kozower BD, Lau CL, Sheng K, et al. Size matters: a comparison of T1 and T2 peripheral non-small-cell lung cancers treated with stereotactic body radiation therapy (SBRT). J Thorac Cardiovasc Surg 2010;140(3):583–9.
32. Allibhai Z, Taremi M, Bezjak A, Brade A, Hope AJ, Sun A, et al. The impact of tumor size on outcomes after stereotactic body radiation therapy for medically inoperable early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2013;87(5):1064–70.
33. Baumann P, Nyman J, Lax I, Friesland S, Hoyer M, Rehn Ericsson S, et al. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol 2006;45(7):787–95.
34. Thompson M, Rosenzweig KE. The evolving toxicity profile of SBRT for lung cancer. Transl Lung Cancer Res 2019;8(1):48–57.